SymBio And Eisai Start Japan Phase II Trials Of Treakisym For Chronic Lymphocytic Leukemia
This article was originally published in PharmAsia News
Executive Summary
SymBio Pharmaceuticals has started Phase II trials in Japan in collaboration with Eisai for Treakisym (bendamustine) for use in treatment of chronic lymphocytic leukemia.